Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?

Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.

Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.

Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.

The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.

Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.

Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.

Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.

But the Galaxies Lung-201 trial features notable omissions, plus toxicity.